OncLive TV

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss which future advances being examined in clinical trials in gynecologic oncology are catching their eyes.

David R. Wise, MD, PhD, unpacks the design of a phase 1b trial of pasritamig plus docetaxel in mCRPC.

Emese Zsiros, MD, PhD, FACOG, discusses the FDA approval of pembrolizumab plus paclitaxel with or without pembrolizumab for PD-L1–positive ovarian cancer.

Rita Nanda, MD, discusses the I-SPY 2 study in patients with breast cancer.

R. Lor Randall, MD, FACS, discusses the clinical utility and global variability of DAIR procedures for periprosthetic joint infection in sarcoma.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss the most interesting recent trends in clinical trials in gynecologic oncology.

Wendy Stock, MD, discusses recommendations from the ASH Guidelines on utilizing pediatric-inspired regimens in adolescent/young adult ALL.

Colin Vale, MD, discusses long-term efficacy data for blinatumomab and ponatinib in Ph+ B-ALL and significance of achieving remission without procedures.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss their approaches to supporting patients with gynecologic malignancies during clinical trials.

Rita Nanda, MD, discusses the importance of clinical trials in breast cancer.

Nicole Lamanna, MD, discusses the FDA approval of first-line acalabrutinib plus venetoclax for CLL and the phase 3 AMPLIFY trial data that supported it.

Marwan G. Fakih, MD, discusses the shift in SCAC management after the approval of retifanlimab and the resulting need for better second-line strategies.

Toni K. Choueiri, MD, discusses the potential clinical effects of data from the phase 3 LITESPARK-022 study.

Rami Komrokji, MD, discusses strategies and barriers for utilizing current risk-stratification tools in myelodysplastic syndromes.

Shubham Pant, MD, MBBS, discusses data from the phase 3 BREAKWATER trial supporting upfront targeted therapy in BRAF V600E–mutant mCRC.

Toni K. Choueiri, MD, discusses safety data from the phase 3 LITESPARK-022 study in ccRCC.

Key experts across oncology specialties share how they prioritize patient safety in their practices related to AE awareness and mitigation strategies.

Laura J. Esserman, MD, MBA, discusses the potential utility of risk-based screening for breast cancer.

Javid Moslehi, MD, discusses the role of the cardiologist in the setting of breast cancer management to facilitate optimal cancer management.

Matthew D. Galsky, MD, discusses data from the phase 3 KEYNOTE-B15 trial in patients with MIBC.

Toni K. Choueiri, MD, discusses prior data that led to the initiation of the LITESPARK-022 trial in ccRCC.

Javid Moslehi, MD, highlights current cardiac monitoring protocols associated with breast cancer drugs and ways to refine these protocols in the future.

Laura J. Esserman, MD, MBA, discusses key results from the WISDOM 1.0 breast cancer screening trial.

Javid Moslehi, MD, explains the intersection of cardiovascular health and oncology when optimizing breast cancer treatment decision-making.

Laura J. Esserman, MD, MBA, explains current gaps with breast cancer screening methods.

R. Lor Randall, MD, FACS, discusses results from an analysis of factors associated with local recurrence risk in nonmetastatic Ewing sarcoma.

Vishal Patel, MD, FAAD, FACMS, discusses the importance of multidisciplinary care for patients with locally advanced or unresectable CSCC.

Alexander T. Pearson, MD, PhD, discusses the role of AI for clinical trial design and enrollment.

Matthew D. Galsky, MD, unpacks the design of the phase 3 KEYNOTE-B15 in patients with MIBC.

Rachna T. Shroff, MD, MS, FASCO, discusses how bringing a diversity of perspectives to clinical trial design has moved the needle in pancreatic cancer.